In 2023, the worldwide market for breast lesion localization was assessed at USD 410.4 million. Projections indicate a growth to USD 653.1 million by 2030, with a compound annual growth rate (CAGR) of 7.0% expected between 2024 and 2030.
This growth of the market can be credited to the increasing breast cancer screening programs and better repayment situations. Furthermore, breast cancer is quite common illness in women and its occurrence is increasing quickly. For example, as per the data issued by the International Agency for Research on Cancer (IARC), breast cancer has now exceeded lung cancer as the most regularly identified cancer globally.
The acceptance of breast lesion localization devices will surge in the coming few years, because of the increasing occurrence of mammary cancer. The lymph nodes underneath the arms are the most typical first recognizable site of breast cancer spread; however, there are few lesions in these nodes that cannot be felt by touch. Furthermore, the malignancy might also spread to other parts of the body.
On the basis of biopsy technique, the CNB category had the largest industry share, of 35%, in 2023. This is mainly credited to its accurateness in the analysis of benign lesions and its ablity to discriminate between in-situ lesions and invasive cancer. Furthermore, CNB is certainly more dependable than fine needle aspiration since it gets a larger tissue sample and offers some architectural information.
On a global scale, North America holds the predominant market share, primarily attributed to the presence of a robust healthcare infrastructure, significant manufacturing entities, heightened awareness regarding early breast cancer detection, streamlined FDA approval procedures, and widespread adoption of advanced medical devices in cancer treatment facilities within the region.
No comments:
Post a Comment